$5.64
9.32% yesterday
Nasdaq, Nov 15, 10:08 pm CET
ISIN
US92915B1061
Symbol
VYGR
Sector
Industry

Voyager Therapeutics, Inc. Stock price

$5.64
-1.21 17.66% 1M
-2.93 34.19% 6M
-2.80 33.18% YTD
-1.09 16.20% 1Y
+2.22 64.91% 3Y
-7.21 56.11% 5Y
-12.11 68.23% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.58 9.32%
ISIN
US92915B1061
Symbol
VYGR
Sector
Industry

Key metrics

Market capitalization $308.09m
Enterprise Value $8.08m
P/E (TTM) P/E ratio 7.83
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.05
P/S ratio (TTM) P/S ratio 1.88
P/B ratio (TTM) P/B ratio 0.93
Revenue growth (TTM) Revenue growth 3.40%
Revenue (TTM) Revenue $163.78m
EBIT (operating result TTM) EBIT $9.08m
Free Cash Flow (TTM) Free Cash Flow $-28.66m
Cash position $345.36m
EPS (TTM) EPS $0.72
P/E forward negative
P/S forward 4.01
EV/Sales forward 0.46
Short interest 6.46%
Show more

Is Voyager Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Voyager Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Voyager Therapeutics, Inc. forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Voyager Therapeutics, Inc. forecast:

Buy
90%
Hold
10%

Financial data from Voyager Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
164 164
3% 3%
100%
- Direct Costs 5.06 5.06
28% 28%
3%
159 159
3% 3%
97%
- Selling and Administrative Expenses 32 32
7% 7%
20%
- Research and Development Expense 112 112
46% 46%
69%
14 14
70% 70%
9%
- Depreciation and Amortization 5.06 5.06
28% 28%
3%
EBIT (Operating Income) EBIT 9.08 9.08
79% 79%
6%
Net Profit 26 26
51% 51%
16%

In millions USD.

Don't miss a Thing! We will send you all news about Voyager Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Voyager Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
3 days ago
Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Q3 2024 Results Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Trista Morrison - Chief Corporate Affairs Officer and Chief of Staff to the CEO Alfred Sandrock - President and Chief Executive Officer Toby Ferguson - Chief Medical Officer Todd Carter - Chief Scientific Officer Nathan Jorgensen - Chief Financial Officer Conferen...
Neutral
GlobeNewsWire
3 days ago
- Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H1 2025 -
Neutral
GlobeNewsWire
10 days ago
LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the Company will participate in multiple upcoming investor conferences:
More Voyager Therapeutics, Inc. News

Company Profile

Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Alfred Sandrock
Employees 162
Founded 2013
Website www.voyagertherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today